Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DTSS NASDAQ:ENGN NASDAQ:IMMX NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTSSDatasea$0.84-6.1%$0.91$0.64▼$2.50$9.35M0.7683,197 shs22,983 shsENGNenGene$1.64-4.7%$4.91$1.40▼$12.25$115.21M-0.32.81 million shs952,721 shsIMMXImmix Biopharma$7.93-5.8%$9.26$1.94▼$11.61$458.14M0.11.37 million shs1.27 million shsSTROSutro Biopharma$26.09-9.0%$30.81$6.74▼$43.85$475.24M1.54322,161 shs295,736 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTSSDatasea-1.51%+13.29%+1.70%+1.70%-59.68%ENGNenGene+2.99%-3.37%-78.20%-80.18%-55.09%IMMXImmix Biopharma-0.24%-4.75%-11.92%-9.36%+308.74%STROSutro Biopharma+5.52%-3.21%-23.15%+13.40%+215.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTSSDatasea$0.84-6.1%$0.91$0.64▼$2.50$9.35M0.7683,197 shs22,983 shsENGNenGene$1.64-4.7%$4.91$1.40▼$12.25$115.21M-0.32.81 million shs952,721 shsIMMXImmix Biopharma$7.93-5.8%$9.26$1.94▼$11.61$458.14M0.11.37 million shs1.27 million shsSTROSutro Biopharma$26.09-9.0%$30.81$6.74▼$43.85$475.24M1.54322,161 shs295,736 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTSSDatasea-1.51%+13.29%+1.70%+1.70%-59.68%ENGNenGene+2.99%-3.37%-78.20%-80.18%-55.09%IMMXImmix Biopharma-0.24%-4.75%-11.92%-9.36%+308.74%STROSutro Biopharma+5.52%-3.21%-23.15%+13.40%+215.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDTSSDatasea 1.00SellN/AN/AENGNenGene 2.21Hold$12.68673.28% UpsideIMMXImmix Biopharma 2.50Moderate Buy$19.50145.90% UpsideSTROSutro Biopharma 3.00Buy$49.1188.24% UpsideCurrent Analyst Ratings BreakdownLatest ENGN, DTSS, IMMX, and STRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026STROSutro Biopharma BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$56.005/28/2026STROSutro Biopharma BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$56.005/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026STROSutro Biopharma Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$38.00 ➝ $43.005/15/2026STROSutro Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $50.005/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/8/2026STROSutro Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.005/8/2026ENGNenGene CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Outperform ➝ Market Perform(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDTSSDatasea$56.89M0.15N/AN/A$0.38 per share2.21ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/ASTROSutro Biopharma$99.61M4.34N/AN/A($15.43) per share-1.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDTSSDatasea-$5.09M-$0.32N/AN/AN/A-4.80%-88.98%-37.33%N/AENGNenGene-$117.30M-$2.25N/AN/AN/AN/A-55.83%-45.74%6/11/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%8/14/2026 (Estimated)STROSutro Biopharma-$191.09M-$11.04N/AN/AN/A-154.21%N/A-69.20%8/6/2026 (Estimated)Latest ENGN, DTSS, IMMX, and STRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026Q2 2026ENGNenGene-$0.48N/AN/AN/AN/AN/A5/14/2026Q1 2026STROSutro Biopharma-$2.7363-$2.94-$0.2037-$2.94$8.89 million$14.52 million5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/9/2026Q1 2026ENGNenGene-$0.55-$0.44+$0.11-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDTSSDataseaN/AN/AN/AN/AN/AENGNenGene$1.5896.40%N/AN/A N/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDTSSDataseaN/A0.600.57ENGNenGene0.0911.7511.75IMMXImmix BiopharmaN/A8.758.75STROSutro BiopharmaN/A3.123.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDTSSDatasea82.07%ENGNenGene64.16%IMMXImmix Biopharma11.26%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipDTSSDatasea50.65%ENGNenGene10.50%IMMXImmix Biopharma30.30%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDTSSDatasea12010.45 million5.16 millionNot OptionableENGNenGene3166.99 million59.95 millionN/AIMMXImmix Biopharma954.41 million37.92 millionOptionableSTROSutro Biopharma24016.57 million15.97 millionOptionableENGN, DTSS, IMMX, and STRO HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Buy" by BrokeragesJune 1, 2026 | americanbankingnews.comNews Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) ForecastsMay 28, 2026 | finance.yahoo.comUS$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These ResultsMay 17, 2026 | finance.yahoo.comWedbush upgrades Sutro Biopharma (STRO)May 16, 2026 | msn.comSutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsMay 14, 2026 | globenewswire.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Moderate Buy" by AnalystsMay 7, 2026 | marketbeat.comSutro Biopharma (STRO) to Release Earnings on ThursdayMay 7, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist FinancialMay 6, 2026 | marketbeat.comCitizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead ProgramMay 1, 2026 | insidermonkey.comMizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendationMay 1, 2026 | msn.comSutro Biopharma: Recycling Past Data Ahead Of The Readout, SellMay 1, 2026 | seekingalpha.comHere is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right NowApril 29, 2026 | finance.yahoo.comSutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - SlideshowApril 24, 2026 | seekingalpha.comSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026April 19, 2026 | markets.businessinsider.comSutro Biopharma Reports Promising Preclinical Data for Next-Generation ADCs STRO-004, STRO-006, and STRO-227 at AACR Annual Meeting 2026April 19, 2026 | quiverquant.comQSutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst UpgradeApril 18, 2026 | defenseworld.netDSutro Biopharma (STRO) price target decreased by 21.62% to 29.58April 9, 2026 | msn.comSutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?April 8, 2026 | zacks.comLeerink Partners initiates coverage of Sutro Biopharma (STRO) with outperform recommendationApril 8, 2026 | msn.comSutro Biopharma (STRO) price target increased by 13.85% to 37.74March 27, 2026 | msn.comWells Fargo upgrades Sutro Biopharma (STRO)March 25, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026ENGN, DTSS, IMMX, and STRO Company DescriptionsDatasea NASDAQ:DTSS$0.84 -0.06 (-6.15%) Closing price 04:00 PM EasternExtended Trading$0.83 -0.01 (-1.67%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Datasea Inc., through its subsidiaries, provides technology and information systems in the People's Republic of China. The company provides smart city solutions and 5G messaging applications. It also offers its smart security solutions primarily to schools, tourist or scenic attractions, and public communities. In addition, the company provides intelligent acoustics products, which include ultrasonic air sterilizer, air purification and deodorization, and other products. The company was formerly known as Rose Rock, Inc. and changed its name to Datasea Inc. in October 2015. Datasea Inc. was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.enGene NASDAQ:ENGN$1.64 -0.08 (-4.65%) Closing price 04:00 PM EasternExtended Trading$1.62 -0.02 (-1.22%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Immix Biopharma NASDAQ:IMMX$7.93 -0.49 (-5.82%) Closing price 04:00 PM EasternExtended Trading$8.18 +0.25 (+3.09%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Sutro Biopharma NASDAQ:STRO$26.09 -2.59 (-9.03%) Closing price 04:00 PM EasternExtended Trading$24.89 -1.20 (-4.61%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
